Table 1.
Clinical trials using disulfiram as monotherapy in cancer patients.
| Phase | Title | Status | Study Results | Cancer | Drug (Monotherapy) | Trial ID & Ref. |
|---|---|---|---|---|---|---|
| I | Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver | Completed | Well tolerated; no dose limiting toxicity; one stable disease | Cancer | Disulfiram Copper Gluconate | NCT00742911 [43] |
| I | Bioavailability of Disulfiram and Metformin in Glioblastomas | Recruiting | N/A | Glioblastoma | Disulfiram | NCT03151772 |
| Ib | A Phase Ib Study of Intravenous Copper Loading with Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer | Terminated | No grade > 3 toxicities; no effect on PSA; 64Cu-PET shows Cu-uptake in some metastases | Prostate Cancer | Disulfiram Copper gluconate | NCT02963051 [45] |
| I/II | Disulfiram in Patients with Metastatic Melanoma | Completed | N/A | Stage IV Melanoma | Disulfiram | NCT00256230 |
| II | Study of Recurrent Prostate Cancer with Rising Prostate Specific Antigen (PSA) | Completed | Moderate tolerability (6/19 with grade 3); 5/19 (26%) patients with change in 5-methyl-cytosine; no effect on PSA levels | Prostate Cancer | Disulfiram | NCT01118741 [46] |
| II | Phase II Trial of Disulfiram with Copper in Metastatic Breast Cancer | Recruiting | N/A | Metastatic Breast Cancer | Disulfiram Copper | NCT03323346 |
| II | Disulfiram and Cisplatin in Refractory TGCTs. | Recruiting | N/A | Germ Cell Tumor | Disulfiram | NCT03950830 |